CDIB Capital Healthcare Ventures II led the series B funding round for Acepodia and helped the company successfully raise US$47 million in a very short period of time. Professional Capital Market Experience. Even during phases of market volatility, our vast resources and experience in the capital market get our partners results. ...

Our industry-leading international team plays a pivotal leading role in Taiwan's venture capital and private equity markets.

CDIB Capital Healthcare Ventures II led the series B funding round for Acepodia and helped the company successfully raise US$47 million in a very short period of time. Professional Capital Market Experience. Even during phases of market volatility, our vast resources and experience in the capital market get our partners results. ...

President, CDIB Capital Healthcare Ventures. Robert Liu Robert Liu. Managing Director, CDIB YIDA Healthcare Fund. Yen Lu Yen Lu. President, CDIB Yida Private Equity (Kunshan) Co. Ltd. Daniel Tsou Daniel Tsou. President, CDIB Private Equity (Fujian) Co. Ltd. Gary Fung Gary Fung.

Alar Pharmaceuticals Inc. (6785 TT) is a new 505 (b) (2) drug development company focused on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorders, chronic pains, and major depressive disorders. Take me to the website. HEADQUARTER.

President of CDIB Capital Healthcare Ventures and CDIB Capital Healthcare Ventures II. An acting president participating in fund establishments since 2012, in charge of planning, constructing and managing fund portfolios. Former director or supervisor for TWi, CCSB, Sharehope, Axiomtek, and RT-Mart. ...

Served as Director on the Board of China Development Industrial Bank (later reincorporated as CDIB Capital Group) and President of CDIB Capital Group till July of 2019, James began his tenure as Chairman of CDIB Capital Healthcare Ventures, and has been engaged in advancing PE fundraising in the biotech sector.

CDIB Capital Healthcare Ventures’ AUM exceeds NT$10bn Healthcare Fund II oversubscribed, to kick off investment in September 2020-07-10 CDF announces preliminary June earnings of NT$986mn, 1H20 accumulative earnings. www.cdibcapitalgroup.com

We offer professional entrepreneurship consulting via the CDIB Capital Innovation Accelerator. This includes recommending partners like FunNow join the AAMA entrepreneurial community, one-on-one encounters with Accelerator mentors who help them solve problems on Startup BoD Day and exclusive "Entrepreneurship Afternoon Tea" for investors to meet celebrity mentors who help the next generation ...

Paul Yang is a non-executive board member of CDF and CDIB Capital Group. He joined Kohlberg Kravis Roberts (“KKR”) as a Partner and CEO of Greater China in 2017. Prior to KKR, Paul was President and CEO of CDF and CDIB, as well as the Chairman of CDIB Capital International. Prior to CDF, Paul served as Managing Director at Development Bank ...